
    
      The study was designed as a double-blind randomized controlled trial, with research assessors
      and patients intended to be blind to the intervention status. The staff members performing
      the assessment were not involved in implementing any aspect of the intervention.162 patients
      were randomized to one of two 24-week individual treatments: metformin (1000mg/day)or
      placebo. Medications were provided in double-blind fashion.The assessments include lipid
      levels, body weight, body mass index, fasting glucose, fasting insulin and insulin resistance
      index.
    
  